Mariana C. Stern, PhD, discusses the biggest gaps identified in the 2026 AACR Cancer Disparities Progress Report and what oncologists can do to combat them.
|Articles|March 4, 2011
Oncology Nursing News
- December 2010
- Volume 4
- Issue 6
Bone Loss Drugs Increase Stroke Risk in Patients With Cancer
Author(s)Onclive Team
Older patients with cancer taking bisphosphonates for bone metastases are at modestly increased risk
Advertisement
Older patients with cancer taking bisphosphonates for bone metastases are at modestly increased risk for atrial fibrillation and stroke. According to a study published online in the Journal of Clinical Oncology, the absolute risk for these patients within 6 years of starting bisphosphonate treatment was approximately 8% for all supraventricular tachycardia events and 4% for stroke.
Articles in this issue
over 15 years ago
Net Guides: Melanomaover 15 years ago
Net Guides: Bone Metastasesover 15 years ago
Yoga for Cancer Careover 15 years ago
FDA Updates: March 7, 2011over 15 years ago
The Future of Nursingover 15 years ago
Net Guides: Liver Cancerover 15 years ago
Net Guides: Carcinoma of Unknown Primary Orginover 15 years ago
Integrative Medicine and Cancer Treatmentover 15 years ago
Reimbursement for Nurse Navigation: It Can Be Doneover 15 years ago
Tools to Help Patients Navigate Their Treatment PathAdvertisement
Related to this article
Pankit Vachhani, MD, discusses the importance of hematocrit control in the management of polycythemia vera.
Hamza Hashmi, MD, discusses the evolving role and implementation of CAR T-cell therapy in early relapsed/refractory multiple myeloma.
Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.
Jill Gilbert, MD, discusses the journey of lifelong learning in hematology/oncology.
Antibodies directed against TNFR2, a regulator in the tumor microenvironment that promotes tumor cell proliferation, have shown promise in T-cell lymphoma and ovarian cancer.
Maurie Markman, MD, discusses conflicts of interest in cancer care.
In an OncLive Peer Exchange, experts discussed the evolving treatment landscape in CLL, spanning frontline selection to emerging next-generation agents.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
3
Dr Viansone on De-Escalating Chemotherapy Type and Duration in HER2-Positive Breast Cancer
4
Novel Approaches for Hematocrit Control Are Driving Research in Polycythemia Vera
5